Pharma double-digit growth delayed to FY27
Pharma double-digit growth originally guided for FY26 is now expected in FY27 due to US FDA impact delaying recovery by a quarter.
HIKAL / guidance tracker
Keep management guidance in view.
Hikal · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Crop protection revenue flat for FY26
Crop protection business expected to remain flat year-on-year for FY26, unchanged from earlier guidance.
Capex of ₹150 crore for FY26
Full-year capex guided at ₹150 crore, down from initial ₹200 crore, with ₹40-50 crore spent in Q4.
Personal care commercialization in FY27
Three to four personal care products to be commercialized in FY27, with two products already commercialized in Q3.
Pharma DMF filings to increase to 5-6 annually
Targeting 5-6 DMF filings per year compared to historical 2-3, leveraging new Panoli facility.
Animal health business to reach 500+ crores in 4-5 years
Reiterated target of building a 500+ crore animal health business over the next 4-5 years.
HPAPI manufacturing facility targeted for FY28
Planned HPAPI manufacturing facility in Pune targeted over FY28.